产品
编 号：F021726
分子式：C21H22N4O3
分子量：378.42
分子式：C21H22N4O3
分子量：378.42
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1050477-31-0
产品详情
生物活性：
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
体内研究：
Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr?mter (MWF) rat.Animal Model:Twelve-week-old MWF rat
Dosage:10 mg/kg
Administration:P.o.; daily for 4 weeks
Result:Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
Animal Model:Twelve-week-old MWF rat
Dosage:10 mg/kg
Administration:P.o.; daily for 4 weeks
Result:Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
体内研究：
Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr?mter (MWF) rat.Animal Model:Twelve-week-old MWF rat
Dosage:10 mg/kg
Administration:P.o.; daily for 4 weeks
Result:Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
Animal Model:Twelve-week-old MWF rat
Dosage:10 mg/kg
Administration:P.o.; daily for 4 weeks
Result:Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备